Antibodies to neural proteins in organophosphorus-induced delayed neuropathy (OPIDN) and its amelioration

El-Fawal, Hassan A. N.; McCain, Wilfred C.

doi:10.1016/j.ntt.2008.01.005

Cited by 12 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study confirming our 2008 [23] findings, NAb, IgG (avian IgY), against NF, GFAP, and MBP were detected in hens as early as 7 days following a single dose of PSP (Figure 2). Titers of anti-NF, but not GFAP or MBP, NAb significantly correlated with changes in gait considered indicative of ataxia in OPIDP, decrease in stride length, and increase in width (Table 3).…”

Section: Applicationsupporting

confidence: 83%

“…Titers of anti-NF, but not GFAP or MBP, NAb significantly correlated with changes in gait considered indicative of ataxia in OPIDP, decrease in stride length, and increase in width (Table 3). The lack of associations with GFAP and MBP is consistent with the primary targeting of neurons in OPIDP, although the earlier study did show associations with anti-MBP, secondary myelin involvement, and scored clinical ataxia [23, 26]. In addition, IgG against AChE was detected in sera of these hens (Figure 3).…”

Section: Applicationsupporting

confidence: 75%

“…This is believed to be independent of anti-AChE activity, although some AChE inhibitors may also precipitate OPIDP. We have previously published result of NAb utility in OPIDP induced by phenyl saligenin phosphate (PSP) and amelioration with calcium channel blockade in the hen, the Environmental Protection Agency's (EPA) mandated model [23]. These results have been confirmed in humans by AbouDonia and colleagues [25].…”

Section: Applicationmentioning

confidence: 92%

See 2 more Smart Citations

Neuroantibody Biomarkers: Links and Challenges in Environmental Neurodegeneration and Autoimmunity

El-Fawal

2014

Autoimmune Diseases

View full text Add to dashboard Cite

The majority of neurodegenerative (ND) and autoimmune diseases (AID) remain idiopathic. The contribution of environmental chemicals to the development of these disorders has become of great interest in recent years. A convergence of mechanism between of ND and AID development has also emerged. In the case of ND, including neurotoxicity, the focus of this review, work over the last two decade in the realm of biomarker development, indicates that the immune response provides a venue whereby humoral immunity, in the form of autoantibodies to nervous system specific proteins, or neuroantibodies (NAb), may provide, once validated, a sensitive high throughput surrogate biomarker of effect with the potential of predicting outcome in absence of overt neurotoxicity/neurodegeneration. In addition, NAb may prove to be a contributor to the progression of the nervous system pathology, as well as biomarker of stage and therapeutic efficacy. There is a compelling need for biomarkers of effect in light of the introduction of new chemicals, such as nanoengineered material, where potential neurotoxicity remains to be defined. Furthermore, the convergence of mechanisms associated with ND and AID draws attention to the neglected arena of angiogenesis in defining the link between environment, ND, and AID.

show abstract

Section: Applicationsupporting

confidence: 83%

Section: Applicationsupporting

confidence: 75%

Section: Applicationmentioning

confidence: 92%

See 1 more Smart Citation

Neuroantibody Biomarkers: Links and Challenges in Environmental Neurodegeneration and Autoimmunity

El-Fawal

2014

Autoimmune Diseases

View full text Add to dashboard Cite

show abstract

“…Changes or expression of autoantibodies precede clinical signs and symptoms of neurological disease providing a much more sensitive marker of damage than late presenting clinical detection as suggested by some animal studies. 32 Loss of these structural proteins, indicated by serum IgG, if pathogenic, may contribute to ND. The present neurological markers have been utilized in several studies illustrating either toxic exposure or disease progress.…”

Section: Discussionmentioning

confidence: 99%

Nervous system autoantibodies and vitamin D receptor gene polymorphisms in hemodialysis patients

Mason

Assimon

Bishop

et al. 2012

Hemodialysis International

View full text Add to dashboard Cite

BACKGROUND Cognitive deficits are prevalent in hemodialysis (HD) patients. Vitamin D deficiency and vitamin D receptor gene (VDR) SNPs have been linked to both neurodegeneration (ND) and neuroprotection, respectively. Autoantibodies (Ab) to myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), and neurofilament (NF) triplet proteins arise secondary to nervous system (NS) damage providing a means to assess neurological injury. Characterization of Ab biomarkers of NS damage in HD patients, their association with VDR SNPs, and nutritional vitamin D (NVD) therapy was performed. METHODS VDR genotypes, cytokines, and Ab biomarkers to NS proteins in HD subjects receiving ergocalciferol (n=40) were compared to non-users (n=71). IL-6, TNF-α, and IgG titers against NFs, GFAP and MBP were measured by immunoassay. Subjects were genotyped for VDR SNPs BsmI (rs1544410) and FokI (rs2228570). RESULTS Subjects (age 63.3±16.1 years, 66% male) who were C allele carriers of BsmI had higher values of NF-68 antibody titers (p = 0.027). Ergocalciferol users (n=40) compared to non-users (n=71) had lower Ab titers to NS proteins, however, only anti-NF160 and anti-MBP titers were significantly (p < 0.05) higher. CONCLUSIONS IgG against NS proteins in HD patients suggests neuronal and glial insult and a relationship with VDR alleles. NVD may provide some neuroprotection, indicated by anti-NF160 and anti-MBP, which was markedly lowered in ergocalciferol patients. This preliminary study suggests Ab detection may be useful in monitoring ND and the potential of NVD for neuroprotection in HD patients.

show abstract

“…Calcium channel blockers were demonstrated to ameliorate PSP-and TOTP-induced OPIDN, as indicated by clinical, electrophysiological, and morphological endpoints (El-Fawal and Ehrich, 1993;El-Fawal et al, 1989, 1990a. Antibodies to proteins indicative of neurodegeneration were also less in serum of hens with OPIDN that had been treated with calcium channel blockers (El-Fawal and McCain, 2008). Clinical signs developed later in hens treated with the calcium channel blockers verapamil and nifedipine.…”

Section: Factors Influencing the Development Of Organophosphorus-indumentioning

confidence: 92%

Organophosphorus-Induced Delayed Neuropathy

Ehrich

Jortner

2010

Hayes' Handbook of Pesticide Toxicology

View full text Add to dashboard Cite

Antibodies to neural proteins in organophosphorus-induced delayed neuropathy (OPIDN) and its amelioration

Cited by 12 publications

References 48 publications

Neuroantibody Biomarkers: Links and Challenges in Environmental Neurodegeneration and Autoimmunity

Neuroantibody Biomarkers: Links and Challenges in Environmental Neurodegeneration and Autoimmunity

Nervous system autoantibodies and vitamin D receptor gene polymorphisms in hemodialysis patients

Organophosphorus-Induced Delayed Neuropathy

Contact Info

Product

Resources

About